Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.352 Factor de Impacto de 5 años: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumes:
Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v30.i1.60
pages 79-93

The Global Problem of Antibiotic Resistance

Thomas D. Gootz
Thomas Gootz Consulting, 14 Dickinson Court, Deep River, CT 06417, USA

SINOPSIS

Amid the recent attention justly focused on the potential problem of microbial sources for weapons of bioterrorism, it is also apparent that human pathogens frequently isolated from infections in patients from community and hospital sources have been growing more resistant to commonly used antibiotics. Much of the growth of multiple-drug-resistant (MDR) bacterial pathogens can be contributed to the overuse of broad-spectrum antimicrobial products. However, an equally troubling and often overlooked component of the problem involves the elegant ways in which pathogenic bacteria continually evolve complex genetic systems for acquiring and regulating an endless array of antibiotic-resistance mechanisms. Efforts to develop new antimicrobials have over the past two decades been woefully behind the rapid evolution of resistance genes developing among both gram-positive and gram-negative pathogens. Several new agents that are best suited for use in the hospital environment have been developed to combat staphylococci resistant to β-lactam antimicrobials following acquisition of the mecA gene. However, the dramatic spread in the US of the now common community strain of Staphylococcus aureus USA300 has shifted the therapeutic need for new antibiotics useful against MRSA to the community. As the pharmaceutical industry focused on discovering new agents for use against MRSA, hospitals in many parts of the world have seen the emergence of gram-negative pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae that are clinically resistant to almost all available antimicrobials. Such MDR isolates usually contain multiple-resistance determinants, including loss of outer membrane porins via gene inactivation by chromosomally encoded insertion sequences, up-regulation of inate efflux pumps, as well as acquisition of drug-inactivating enzymes whose genes are encoded on self-transmissible plasmids, integrons, and complex transposable elements. These determinants confer a complex resistance phenotype that is often superimposed on mutations in the primary drug target in the cell. The continued evolution of such a complex array of antibiotic-resistance genes presents a formidable challenge at a time when large pharmaceutical companies have scaled down their presence in the anti-infectives arena.


Articles with similar content:

Algal-Produced Immunotoxins
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 3-4
Jonathan L. Torres, Amy T. Hoang, Miller Tran, Michael P. Mayfield, James S. Hyun, Stephen P. Mayfield
SCE Jumping: Genetic Tool for Allelic Exchange in Bacteria
Critical Reviews™ in Eukaryotic Gene Expression, Vol.14, 2004, issue 1&2
Sandy M. Wong
Expression of Hygromycin B Resistance in Oyster Culinary-Medicinal Mushroom, Pleurotus ostreatus (Jacq.:Fr.)P. Kumm. (Higher Basidiomycetes) Using Three Gene Expression Systems
International Journal of Medicinal Mushrooms, Vol.14, 2012, issue 1
Xiaoya Dong, Liyou Qiu, Jinwen Shen, Ke Zhang, Yuancheng Qi, Yuqian Gao
Endothelial Responses to Bacterial Toxins in Sepsis
Critical Reviews™ in Immunology, Vol.23, 2003, issue 4
Friedrich Grimminger, Ulrich Grandel
Colorectal Cancer: A Multipathway Disease
Critical Reviews™ in Oncogenesis, Vol.12, 2006, issue 3-4
Jeremy R. Jass